Search

Search Constraints

You searched for: Author/Creator Inati, Adlette

Search Results

1. 13‐valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6‐17 years of age with sickle cell disease previously vaccinated with 23‐valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. Issue 8 (23rd March 2015)

2. 13‐valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6‐17 years of age with sickle cell disease previously vaccinated with 23‐valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. Issue 8 (23rd March 2015)

4. A dose‐escalation phase IIa study of 2, 2‐dimethylbutyrate (HQK‐1001), an oral fetal globin inducer, in sickle cell disease. Issue 11 (3rd October 2013)

5. A double‐blind, placebo‐controlled phase II study of the efficacy and safety of 2, 2‐dimethylbutyrate (HQK‐1001), an oral fetal globin inducer, in sickle cell disease. Issue 7 (15th April 2014)

7. A phase 2 study of HQK‐1001, an oral fetal haemoglobin inducer, in β‐thalassaemia intermedia. (13th November 2013)

8. A randomized phase I/II trial of HQK‐1001, an oral fetal globin gene inducer, in β‐thalassaemia intermedia and HbE/β‐thalassaemia. (27th March 2013)

9. Clinical Features and Outcome of Sickle Cell Disease in a Tertiary Center in Northern Lebanon: A Retrospective Cohort Study in a Local, Hospital-Associated Registry. (4th March 2021)